IL280733B2 - Method and kit for treating abnormal hollowed space - Google Patents
Method and kit for treating abnormal hollowed spaceInfo
- Publication number
- IL280733B2 IL280733B2 IL280733A IL28073321A IL280733B2 IL 280733 B2 IL280733 B2 IL 280733B2 IL 280733 A IL280733 A IL 280733A IL 28073321 A IL28073321 A IL 28073321A IL 280733 B2 IL280733 B2 IL 280733B2
- Authority
- IL
- Israel
- Prior art keywords
- blood
- kit
- abnormal
- hollowed space
- coagulation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 36
- 230000002159 abnormal effect Effects 0.000 title claims description 32
- 239000008280 blood Substances 0.000 claims description 50
- 210000004369 blood Anatomy 0.000 claims description 50
- 230000015271 coagulation Effects 0.000 claims description 29
- 238000005345 coagulation Methods 0.000 claims description 29
- 239000003146 anticoagulant agent Substances 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 206010016717 Fistula Diseases 0.000 claims description 9
- 230000003890 fistula Effects 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- 208000004680 Rectal Fistula Diseases 0.000 claims description 6
- 206010002156 anal fistula Diseases 0.000 claims description 6
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 229960004494 calcium gluconate Drugs 0.000 claims description 5
- 239000004227 calcium gluconate Substances 0.000 claims description 5
- 235000013927 calcium gluconate Nutrition 0.000 claims description 5
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 5
- 239000005995 Aluminium silicate Substances 0.000 claims description 4
- 235000012211 aluminium silicate Nutrition 0.000 claims description 4
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 claims description 3
- -1 Calcium Gluconate) Chemical class 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 3
- 102000007327 Protamines Human genes 0.000 claims description 3
- 108010007568 Protamines Proteins 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 229950008679 protamine sulfate Drugs 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 230000010100 anticoagulation Effects 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/00491—Surgical glue applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/005—Medical syringes, e.g. enemata; Irrigators comprising means for injection of two or more media, e.g. by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/00491—Surgical glue applicators
- A61B2017/00495—Surgical glue applicators for two-component glue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00641—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closing fistulae, e.g. anorectal fistulae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B2017/00831—Material properties
- A61B2017/00884—Material properties enhancing wound closure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Description
METHOD AND KIT FOR TREATING ABNORMAL HOLLOWED SPACE TECHNOLOGICAL FIELD The present disclosure is in the field of medical treatment of abnormal hollowed space in a subject, in particular fistula or anal fistula.
BACKGROUND ART References considered to be relevant as background to the presently disclosed subject matter are listed below:- WO 2019/058373- WO 2019/058375- US 9,180,142Acknowledgement of the above references herein is not to be inferred as meaning that these are in any way relevant to the patentability of the presently disclosed subject matter.
GENERAL DESCRIPTION The present disclosure provides a method and a kit for treating an abnormal hollowed space of a subject, such as a fistula or anal fistula. The method utilizes the blood of the subject by introducing it into the abnormal hollowed space and let it clot within the abnormal hollowed space thereby forming a clot therein that enhances healing process of the abnormal hollowed space.Thus, a first aspect of the present disclosure provides a method for treating an abnormal hollowed space or a cavity of a subject. The method includes: (i) obtaining or withdrawing whole blood from the subject. This may be performed by any known manner in the art. The method further includes (ii) mixing the subject's blood with one or more coagulation agents or anti-anticoagulation agents to thereby initiate clotting process of the blood. Then, (iii) prior to complete coagulation of the blood, introducing, e.g. injecting, the blood with the coagulation agent into said hollowed space and (iv) permitting the blood to coagulate in said abnormal hollowed space until a complete coagulation is obtained, and a clot is formed within the abnormal hollowed space.
In some embodiments of the method, (i) comprises withdrawing whole blood from the subject and mixing it with an anticoagulation agent. This allows to control the coagulation process and controllably induce the coagulation process at any desired time.In some embodiments of the method, the anticoagulant is selected from a list consisting of: ACD-A (Anticoagulant Citrate Dextrose, Solution A), EDTA (ethylenediaminetetraacetic Acid), EGTA (ethylene glycol tetraacetic acid), a citrate, Heparin and oxalate.In some embodiments, the method further comprising, in the instance that said hollowed space has two or more openings, sealing one or more openings of the hollowed space, e.g. a distal opening of the fistula, thus creating a sinus, namely maintaining only one opening open. This step is carried out any time prior to (iii).In some embodiments of the method, (iv) comprises applying a medical dressing or a seal onto an opening of the hollowed space to prevent leakage of blood from the abnormal hollowed space or sinus, therefore ensuring its clotting therein.In some embodiments of the method, said applying a medical dressing or a seal onto an opening of the hollowed space is performed after a period of between 3-minutes from said introducing, or after a period of between 1, 2, 3, 4, 5, 6, 7, 8 and 10, 11, 12, 13, 14, 15, 16 minutes, or about 9 minutes. It is to be noted that this period is the time frame for permitting the blood to coagulate with the abnormal hollowed space. In some embodiments, this time frame can be less than 10, 9, 8, 7, 6, 5, 4, 3, 2 or at times less than 1 minute.The term "about" should be understood as a deviation of up to 20% from the nominated value. For example, a period of about 10 minutes is referred to any period of between 8-12 minutes.In some embodiments of the method, the one or more coagulation agents are in a liquid or a powder form.In some embodiments of the method, the one or more coagulation agents or anti- anticoagulating agents are selected from: Kaolin, Ca2+ (e.g. in the form of calcium salts such as Calcium Gluconate), Mg2+, negatively charged phospholipid (PL) and protamine sulfate.In some embodiments of the method, (ii) comprises first mixing the blood with Calcium Gluconate followed by mixing the blood and Calcium Gluconate mixture with Kaolin.
In some embodiments of the method, said hollowed space is a fistula. In some embodiments of the method, said fistula is an anal fistula.In some embodiments of the method, the hollowed space is a sinus.In some embodiments of the method, the blood is introduced or injected into the abnormal hollowed space in an injection profile. The injection profile comprises first injecting the blood to a distal end of the hollowed space and terminating the injection at a proximal end of the abnormal hollowed space. This profile allows to prevent the inflation of the abnormal hollowed space, e.g. the fistula, in case it is flexible and to ensure that blood is injected to any part of the abnormal hollowed space.In some embodiments of the method, (ii) and (iii) are performed simultaneously. Namely, while introducing or injecting the blood into the abnormal hollowed space, the blood is being mixed with one or more coagulation agents or anti-anticoagulation agents.In some embodiments of the method, prior to (iii), the method further comprising sealing the opening of the abnormal hollowed space with a seal having an injection port, and then performing (iii) wherein the introducing is carried out via the injection port.Yet another aspect of the present disclosure provides a kit for use in the treatment an abnormal hollowed space or cavity of a subject. The kit comprising one or more blood withdrawal devices for allowing withdrawal of blood from the subject; one or more blood collection receptacles for receiving the blood withdrawn from the subject; a coagulation assembly configured for permitting mixture of the withdrawn blood with one or more coagulation agents for initiating coagulation process of the withdrawn blood; and an applicator for introducing the incomplete coagulated blood into the hollowed space.In some embodiments of the kit, the one or more collection receptacles are vacuum tubes.In some embodiments of the kit, the coagulation assembly comprises a volume for introducing the withdrawn blood, said volume is contactable or mixable with one or more coagulation agents or anti-anticoagulation agents for facilitating the mixture of the one or more coagulation agents or anti-anticoagulation agents with the blood within the volume.In some embodiments, the kit further comprising one or more anticoagulation agents for mixing with the withdrawn blood to prevent its natural coagulation process and allow to controllably induce its coagulation process at a desired time.
In some embodiments of the kit, the one or more anti-coagulation agents are comprised within said one or more blood collection receptacles.In some embodiments of the kit, the anticoagulation agent is selected from a list consisting of: ACD-A (Anticoagulant Citrate Dextrose, Solution A), EDTA (ethylenediaminetetraacetic Acid), EGTA (ethylene glycol tetraacetic acid), a citrate, Heparin and oxalate.In some embodiments of the kit, the one or more coagulation agents or anti- anticoagulating agents are selected from: Kaolin, Ca2+ (e.g. in the form of calcium salts such as Calcium Gluconate), Mg2+, negatively charged phospholipid (PL) and protamine sulfate.In some embodiments, the kit further comprising a seal for sealing an opening of the abnormal hollowed space. The seal comprises an injection port for allowing injection of the coagulating blood into the abnormal hollowed space via the seal.In some embodiments of the kit, the abnormal hollowed space is a fistula. In some embodiments of the kit, the fistula is an anal fistula.In some embodiments of the kit, the abnormal hollowed space is a sinus.It is to be noted that the term "sinus" refers to a sac or cavity in any organ or tissue, or an abnormal cavity or passage caused by the destruction of tissue.In some embodiments, the kit is intended for use in a method for treating an abnormal hollowed space or cavity of a subject. The method comprising:(i) withdrawing or obtaining whole blood from the subject;(ii) mixing the subject's blood with one or more coagulation agents or antianticoagulation agents;(iii) prior to complete coagulation of the blood, introducing the blood with the coagulation agent into said hollowed space; and(iv) permitting the blood to coagulate in said space until a complete coagulation is obtained, and a clot is formed within the abnormal hollowed space.In some embodiments, the kit is intended to be used in any of the above embodiments of the method.
BRIEF DESCRIPTION OF THE DRAWINGS In order to better understand the subject matter that is disclosed herein and to exemplify how it may be carried out in practice, embodiments will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which: Figs. 1A-1Dare schematic illustrations presenting different stages of a nonlimiting example of the method according to an aspect of the present disclosure. Figs. 2A-2Bare flow diagrams of non-limiting examples of different embodiments of the method according to an aspect of the present disclosure.
Claims (10)
1. A kit for use in the treatment of an abnormal hollowed space of a subject, the kitcomprising:one or more blood withdrawal devices for allowing withdrawal of blood from the subject;one or more blood collection receptacles for receiving the blood withdrawn from the subject;a coagulation assembly configured for permitting mixture of the withdrawn blood with one or more coagulation agents for initiating coagulation process of the withdrawn blood; andan applicator for introducing the incomplete coagulated blood into the hollowed space;wherein the kit is for use in a method for treating said abnormal hollowed space of the subject, the method comprising(i) withdrawing whole blood from the subject;(ii) mixing the subject's blood with said one or more coagulationagents or anti-anticoagulation agents;(iii) following said mixing and while the blood is still in a flowableform, introducing the blood with the coagulation agent into said hollowed space; andpermitting the blood to coagulate in said space;wherein said abnormal hollowed space is a fistula or anal fistula.
2. The kit of claim 1, wherein said one or more collection receptacles are vacuumtubes.
3. The kit of claim 1 or 2, wherein the coagulation assembly comprises a volume forintroducing the withdrawn blood, said volume is contactable with one or more coagulation agents or anti-anticoagulation agents.
4. The kit of any one of claims 1-3, comprising one or more anticoagulation agentsfor mixing with the withdrawn blood.
5. The kit of claim 4, wherein the one or more anti-coagulation agents are comprisedwithin said one or more blood collection receptacles. - 8 -
6. The kit of claim 4 or 5, wherein the anticoagulation agent is selected from agroupd consisting of: ACD-A (Anticoagulant Citrate Dextrose, Solution A), EDTA (ethylenediaminetetraacetic Acid), EGTA (ethylene glycol tetraacetic acid), a citrate, Heparin and oxalate.
7. The kit of any one of claims 1-6, said one or more coagulation agents or anti-anticoagulating agents are selected from: Kaolin, Ca2+ (e.g. in the form of calcium salts such as Calcium Gluconate), Mg2+, negatively charged phospholipid (PL) and protamine sulfate.
8. The kit of any one of claims 1-7, comprising a seal for sealing an opening of saidabnormal hollowed space, said seal comprises an injection port for allowing injection of blood to the abnormal hollowed space via said seal.
9. The kit of any one of claims 1-8, wherein said abnormal hollowed space is an analfistula.
10. The kit of any one of claims 1-9, wherein said abnormal hollowed space is a sinus. 15
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL280733A IL280733B2 (en) | 2021-02-08 | 2021-02-08 | Method and kit for treating abnormal hollowed space |
| KR1020237029653A KR20230146552A (en) | 2021-02-08 | 2022-02-06 | Methods and kits for treating abnormal empty spaces |
| JP2023547065A JP2024509696A (en) | 2021-02-08 | 2022-02-06 | Methods and kits for treating abnormal cavity spaces |
| US18/275,782 US20240100091A1 (en) | 2021-02-08 | 2022-02-06 | Method and kit for treating abnormal hollowed space |
| EP22705596.9A EP4288070A1 (en) | 2021-02-08 | 2022-02-06 | Method and kit for treating abnormal hollowed space |
| PCT/IL2022/050154 WO2022168099A1 (en) | 2021-02-08 | 2022-02-06 | Method and kit for treating abnormal hollowed space |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL280733A IL280733B2 (en) | 2021-02-08 | 2021-02-08 | Method and kit for treating abnormal hollowed space |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL280733A IL280733A (en) | 2022-09-01 |
| IL280733B1 IL280733B1 (en) | 2023-03-01 |
| IL280733B2 true IL280733B2 (en) | 2023-07-01 |
Family
ID=83103554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL280733A IL280733B2 (en) | 2021-02-08 | 2021-02-08 | Method and kit for treating abnormal hollowed space |
Country Status (1)
| Country | Link |
|---|---|
| IL (1) | IL280733B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL286333B2 (en) * | 2021-09-13 | 2023-04-01 | Reddress Ltd | Device and method for vaginal tissue treatment |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019150355A1 (en) * | 2018-01-30 | 2019-08-08 | Reddress Ltd. | Blood applicator for tissue treatment |
-
2021
- 2021-02-08 IL IL280733A patent/IL280733B2/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019150355A1 (en) * | 2018-01-30 | 2019-08-08 | Reddress Ltd. | Blood applicator for tissue treatment |
Non-Patent Citations (2)
| Title |
|---|
| GIOVANNI BISCEGLIA, MICHELE SANTODIROCCO, AUGUSTA FAIENZA, NICOLA MASTRODONATO, FILOMENA URBANO, ANGELA TOTARO, FRANCESCA BAZZOCCH, BISCEGLIA, 12 February 2020 (2020-02-12) * |
| KUSHNIR, IGAL ET AL., KUSHNIR ET AL., 9 September 2016 (2016-09-09) * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL280733B1 (en) | 2023-03-01 |
| IL280733A (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7333425B2 (en) | Surgical method using purified amphipathic peptide composition | |
| US5773033A (en) | Fibrinogen/chitosan hemostatic agents | |
| US5437292A (en) | Method for sealing blood vessel puncture sites | |
| EP1442709A1 (en) | Vascular sealant delivery device and sheath introducer | |
| RU2560843C2 (en) | Method of obtaining, at least, one compound from blood and device for extraction for application in realisation thereof | |
| US20240100091A1 (en) | Method and kit for treating abnormal hollowed space | |
| US7458974B1 (en) | Apparatus and method for electrically induced thrombosis | |
| CA2375319C (en) | Clotting cascade initiating apparatus and methods of use | |
| IL280733B2 (en) | Method and kit for treating abnormal hollowed space | |
| EP4297662A1 (en) | Kit for treating damaged nerves | |
| WO2023119274A1 (en) | Method and kit for treating a damaged connective tissue | |
| CA2306629A1 (en) | Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma | |
| IL287589A (en) | Method and kit for treating abnormal hollowed space | |
| RU2558995C1 (en) | Method of treating acute anal fissure | |
| US10687849B2 (en) | Materials and methods of using the same to improve structural integrity of a wall of a mammalian luminal organ | |
| Denny et al. | The coagulation of blood in the pleural cavity | |
| RU2599874C2 (en) | Method of treatment of chronic odontogenic osteomyelitis in drug-addicts patients | |
| JPWO2022168099A5 (en) | ||
| US20250065016A1 (en) | Method and kit for treating a damaged connective tissue | |
| CN110693906A (en) | Comprehensive extraction method of autologous white blood cells and platelet plasma | |
| RU2565096C1 (en) | Method for fistula closure in dehiscence of duodenal stump | |
| RU2321427C1 (en) | Method for treating subcapsular hematomas of parenchymatous organs | |
| Hasabe et al. | Comparison between three instruments for total laparoscopic hysterectomy: Harmonic scalpel, ligasure, and bipolar shearer | |
| RU2639422C1 (en) | Method for treatment of heavy liver lesion with posttraumatic coagulopathy | |
| Goodman | A HISTOLOGICAL STUDY OF THE CIRCULAR SUTURE OF THE BLOOD-VESSELS |